title: Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women.
abstract: BACKGROUND
  Mechanisms of the vasoprotective effect of hormone replacement therapy (HRT) are not completely understood, and they may involve direct actions on blood vessels through modulation of endogenous vasoconstrictors and vasodilators. Most studies have focused on estrogen action on prostacyclin and nitric oxide, while insufficient data exist concerning the effect of estrogen replacement therapy (ERT) on vascular endothelial growth factor (VEGF) and prostaglandin E(2).
  
  
  OBJECTIVE
  The aim of this study was to examine the effect of transdermal estrogen therapy on VEGF, prostaglandin E(2) and active renin in normotensive postmenopausal women.
  
  
  METHODS
  Transdermal estrogen (Climara) (Schering): 50 microg 17beta-estradiol) was given for 3 months to normotensive women with a surgically induced menopause, and serum levels of VEGF, active renin and prostaglandin E(2) were measured before and after treatment. In addition, 24-h ambulatory blood pressure monitoring was carried out to determine the estrogen action on mean diurnal and nocturnal systolic and diastolic blood pressure levels.
  
  
  RESULTS
  Estradiol treatment resulted in a significant increase in both VEGF and prostaglandin E(2). There was no significant change in active renin levels. However, out-patient monitoring showed a significant fall in systolic blood pressure (daytime, night-time and total 24-h). The stimulating action of ERT on VEGF and prostaglandin E(2) suggests that both factors can elicit estrogen vasodilatory effects.
  
  
  CONCLUSIONS
  The estrogen-mediated increase in serum VEGF and prostaglandin E(2) concentrations may be a mechanism by which HRT benefits the cardiovascular system.
authors.affiliation: Clinical Center of Endocrinology and Gerontology, Medical University, Sofia, Bulgaria.
authors.forename: S
authors.initials: S
authors.lastname: Zacharieva
authors.forename: I
authors.initials: I
authors.lastname: Atanassova
authors.forename: G
authors.initials: G
authors.lastname: Kirilov
authors.forename: K
authors.initials: K
authors.lastname: Kalinov
authors.forename: R
authors.initials: R
authors.lastname: Shigarminova
authors.forename: E
authors.initials: E
authors.lastname: Nachev
authors.forename: N
authors.initials: N
authors.lastname: Aslanova
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory; D002940:Circadian Rhythm; D015232:Dinoprostone / Q000097:blood; D004334:Drug Administration Schedule; D016228:Endothelial Growth Factors / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D008222:Lymphokines / Q000097:blood / Q000187:drug effects; D008875:Middle Aged; D010052:Ovariectomy; D017698:Postmenopause; D012016:Reference Values; D012083:Renin / Q000097:blood / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D004958:Estradiol; D012083:Renin; D015232:Dinoprostone